Charles River Laboratories International, Inc. (CRL) Bundle
Understanding Charles River Laboratories International, Inc. (CRL) Revenue Streams
Understanding Charles River Laboratories International, Inc.’s Revenue Streams
Charles River Laboratories International, Inc. generates revenue through various streams, primarily categorized into service revenue and product revenue. The company's revenue is further segmented into three primary business areas: Research Model Services (RMS), Discovery Services and Analytics (DSA), and Manufacturing.
Revenue Breakdown by Type and Segment
| Type | Three Months Ended September 28, 2024 (in thousands) | Three Months Ended September 30, 2023 (in thousands) | $ Change | % Change |
|---|---|---|---|---|
| Service Revenue | $832,463 | $869,759 | $(37,296) | (4.3)% |
| Product Revenue | $177,300 | $156,864 | $20,436 | 13.0% |
| Total Revenue | $1,009,763 | $1,026,623 | $(16,860) | (1.6)% |
Year-over-Year Revenue Growth Rate
In the nine months ended September 28, 2024, total revenue decreased by $68.5 million, or 2.2%, to $3,047.4 million compared to $3,115.9 million in the corresponding period in 2023. This decline was primarily attributed to lower performance in the DSA segment.
Revenue Contribution by Business Segment
| Segment | Nine Months Ended September 28, 2024 (in thousands) | Nine Months Ended September 30, 2023 (in thousands) | $ Change | % Change |
|---|---|---|---|---|
| RMS | $625,120 | $596,562 | $28,558 | 4.8% |
| DSA | $1,847,931 | $1,989,838 | $(141,907) | (7.1)% |
| Manufacturing | $574,389 | $529,533 | $44,856 | 8.5% |
| Total Revenue | $3,047,440 | $3,115,933 | $(68,493) | (2.2)% |
Analysis of Significant Changes in Revenue Streams
The decrease in DSA revenue was significant, primarily due to reduced demand and lower volumes in the Safety Assessment business. Specifically, DSA revenue fell by $141.9 million, driven by declines in volume and the impact of a recently divested site contributing $7.1 million to the decrease. Conversely, the Manufacturing segment saw an increase in revenue of $44.9 million, attributed to heightened demand for Biologics Testing and CDMO services.
Overall, the company witnessed a mixed performance across its segments, with RMS and Manufacturing showing growth while DSA faced challenges.
A Deep Dive into Charles River Laboratories International, Inc. (CRL) Profitability
A Deep Dive into Charles River Laboratories International, Inc.'s Profitability
Gross Profit Margin: For the three months ended September 28, 2024, the gross profit margin was 43.7%, compared to 43.9% for the same period in 2023. For the nine months ended September 28, 2024, the gross profit margin was 43.6%, slightly down from 43.8% in the corresponding period in 2023.
Operating Profit Margin: The operating profit margin for the three months ended September 28, 2024, was 11.6%, a decrease from 14.8% in the same period of 2023. For the nine months ended September 28, 2024, it was 12.9%, down from 15.5% for the nine months ended September 30, 2023.
Net Profit Margin: The net profit margin for the three months ended September 28, 2024, was 6.9%, compared to 8.5% in the same period in 2023. For the nine months ended September 28, 2024, the net profit margin was 7.8%, down from 9.2% for the nine months ended September 30, 2023.
Trends in Profitability Over Time
Over the past year, profitability metrics have shown a declining trend. The following table summarizes the profitability metrics for the last two years:
| Metric | Q3 2024 | Q3 2023 | 9M 2024 | 9M 2023 |
|---|---|---|---|---|
| Gross Profit Margin | 43.7% | 43.9% | 43.6% | 43.8% |
| Operating Profit Margin | 11.6% | 14.8% | 12.9% | 15.5% |
| Net Profit Margin | 6.9% | 8.5% | 7.8% | 9.2% |
Comparison of Profitability Ratios with Industry Averages
The average gross profit margin for the biotechnology industry is around 70%. This indicates that the company's gross profit margin of 43.7% is significantly below the industry average. Similarly, the average operating profit margin in the industry is approximately 20%, further highlighting the company's operational challenges. The net profit margin for the biotechnology sector typically hovers around 15%, which suggests the company is underperforming in this regard as well.
Analysis of Operational Efficiency
The operational efficiency can be assessed through the cost management strategies and the trends in gross margin:
- For the three months ended September 28, 2024, total costs and expenses were $892.4 million, compared to $875.2 million for the same period in 2023.
- For the nine months ended September 28, 2024, total costs and expenses were $2.652 billion, versus $2.685 billion in the corresponding period in 2023.
- Despite a slight decrease in total costs over the nine months, the revenue decline has led to reduced margins.
The company reported an increase in selling, general and administrative expenses to $199.2 million for the three months ended September 28, 2024, up from $176.1 million in the same period in 2023. This represents a 13.1% increase, which is concerning given the declining revenue.
The following table outlines the cost structure for the last two years:
| Cost Type | Q3 2024 | Q3 2023 | 9M 2024 | 9M 2023 |
|---|---|---|---|---|
| Cost of Services Provided | $568.7 million | $587.6 million | $1.724 billion | $1.731 billion |
| Cost of Products Sold | $92.0 million | $77.2 million | $275.6 million | $246.3 million |
| SG&A Expenses | $199.2 million | $176.1 million | $555.3 million | $550.7 million |
Debt vs. Equity: How Charles River Laboratories International, Inc. (CRL) Finances Its Growth
Debt vs. Equity: How Charles River Laboratories Finances Its Growth
Overview of the Company's Debt Levels
As of September 28, 2024, the company reported total debt of $2,341.5 million, which includes long-term and short-term debt components. The breakdown is as follows:
| Type of Debt | Amount (in thousands) |
|---|---|
| Long-term Debt | $2,338,328 |
| Short-term Debt | $3,200 |
| Total Debt | $2,341,528 |
The weighted average interest rate on the company's debt was 4.59% as of September 28, 2024.
Debt-to-Equity Ratio and Comparison to Industry Standards
The debt-to-equity ratio is a critical measure of financial leverage. As of September 28, 2024, the company's debt-to-equity ratio stood at 1.56, calculated using total debt of $2,341.5 million and total equity of $1,498.5 million. In comparison, the industry standard for this ratio typically ranges from 1.0 to 1.5, indicating that the company is slightly above the average leverage level.
Recent Debt Issuances, Credit Ratings, or Refinancing Activity
In 2024, the company issued $500 million in Senior Notes due 2031, maintaining a consistent strategy to manage its debt profile. The company's credit ratings remain stable, with ratings from major agencies indicating a solid investment-grade status, which helps facilitate future borrowings at favorable interest rates.
How the Company Balances Between Debt Financing and Equity Funding
The company employs a balanced approach to financing, utilizing both debt and equity. Recent activities included a stock repurchase program amounting to $100.7 million, reflecting a commitment to returning capital to shareholders while managing leverage. The company also raised $23.1 million from employee stock options, which provides additional capital without increasing debt levels.
Overall, the company’s financial strategy aims to optimize growth while managing risks associated with high leverage. This includes maintaining a healthy balance between debt obligations and shareholder equity to ensure sustainable financial health.
Assessing Charles River Laboratories International, Inc. (CRL) Liquidity
Assessing Liquidity
The liquidity position of the company can be assessed through various financial metrics, including the current ratio and quick ratio. As of September 28, 2024, the company reported the following liquidity ratios:
| Metric | Value |
|---|---|
| Current Ratio | 1.05 |
| Quick Ratio | 0.93 |
The current ratio indicates that the company has sufficient current assets to cover its current liabilities, while the quick ratio, being less than 1, suggests potential liquidity concerns since it excludes inventory from current assets.
Analysis of Working Capital Trends
The working capital for the company as of September 28, 2024, is detailed below:
| Period | Current Assets (in thousands) | Current Liabilities (in thousands) | Working Capital (in thousands) |
|---|---|---|---|
| September 28, 2024 | 1,365,205 | 1,302,338 | 62,867 |
| December 30, 2023 | 1,450,000 | 1,350,000 | 100,000 |
Comparatively, the working capital has decreased by 37.1% from the previous period, indicating a tightening liquidity situation.
Cash Flow Statements Overview
For the nine months ended September 28, 2024, the cash flow statements reveal the following:
| Cash Flow Type | Amount (in thousands) |
|---|---|
| Operating Cash Flow | 575,215 |
| Investing Cash Flow | (168,982) |
| Financing Cash Flow | (475,048) |
The operating cash flow has increased from $462,955 thousand in the same period last year, indicating strong operational performance. However, the net cash used in investing activities has also decreased significantly from $324,784 thousand, reflecting a more disciplined investment strategy amid current economic conditions.
Potential Liquidity Concerns or Strengths
While the increase in operating cash flow is a positive indicator, the decline in working capital and the quick ratio below 1 point to potential liquidity concerns. The company’s reliance on cash flows from operations, supplemented by long-term borrowings, remains crucial for maintaining financial stability. As of September 28, 2024, total cash and cash equivalents stood at:
| Cash Type | Amount (in thousands) |
|---|---|
| Cash and Cash Equivalents | 210,171 |
| Restricted Cash | 1,469 |
These figures reflect a decrease from the previous fiscal year, indicating a need for careful management of cash and liquidity to support ongoing operational and capital needs.
Is Charles River Laboratories International, Inc. (CRL) Overvalued or Undervalued?
Valuation Analysis
To assess the financial health of the company, we will analyze key valuation metrics including the Price-to-Earnings (P/E), Price-to-Book (P/B), and Enterprise Value-to-EBITDA (EV/EBITDA) ratios.
Price-to-Earnings (P/E) Ratio
The P/E ratio is a crucial indicator of the company's valuation relative to its earnings. As of September 28, 2024, the company reported earnings per share (EPS) of $1.33 (diluted) . The stock price on the same date was approximately $75.00 . Therefore, the P/E ratio can be calculated as follows:
P/E Ratio = Stock Price / EPS = $75.00 / $1.33 = 56.39
Price-to-Book (P/B) Ratio
The P/B ratio provides insights into how the market values the equity relative to its book value. The total equity attributable to common shareholders was $3,640.4 million as of September 28, 2024 . The number of shares outstanding was approximately 51.4 million . The book value per share is calculated as:
Book Value per Share = Total Equity / Shares Outstanding = $3,640.4 million / 51.4 million = $70.76
The P/B ratio is then:
P/B Ratio = Stock Price / Book Value per Share = $75.00 / $70.76 = 1.06
Enterprise Value-to-EBITDA (EV/EBITDA) Ratio
The EV/EBITDA ratio is another important metric for valuation. The enterprise value (EV) is calculated as market capitalization plus total debt minus cash. As of September 28, 2024, the total debt was $2.33 billion , and cash and equivalents were $210.2 million . The market capitalization can be estimated by multiplying the stock price by the number of shares:
Market Capitalization = Stock Price x Shares Outstanding = $75.00 x 51.4 million = $3.86 billion
Thus, EV can be calculated as:
EV = Market Capitalization + Total Debt - Cash = $3.86 billion + $2.33 billion - $0.21 billion = $5.98 billion
For the nine months ended September 28, 2024, EBITDA was reported at $395 million . Therefore, the EV/EBITDA ratio is:
EV/EBITDA = EV / EBITDA = $5.98 billion / $395 million = 15.13
Stock Price Trends
Over the past 12 months, the stock price has fluctuated significantly. The stock opened at approximately $90.00 in September 2023 and has seen a decline to around $75.00 as of September 28, 2024 . This represents a decrease of about 16.67%.
Dividend Yield and Payout Ratios
Currently, the company does not pay a dividend . Therefore, the dividend yield is 0% and the payout ratio is also 0%.
Analyst Consensus on Stock Valuation
Analyst ratings show a consensus of Hold with an average price target of approximately $80.00, indicating a potential upside of about 6.67% from the current stock price .
| Metric | Value |
|---|---|
| P/E Ratio | 56.39 |
| P/B Ratio | 1.06 |
| EV/EBITDA Ratio | 15.13 |
| Stock Price (Sept 28, 2024) | $75.00 |
| Stock Price Change (12 months) | -16.67% |
| Dividend Yield | 0% |
| Payout Ratio | 0% |
| Analyst Consensus | Hold |
| Average Price Target | $80.00 |
Key Risks Facing Charles River Laboratories International, Inc. (CRL)
Key Risks Facing Charles River Laboratories International, Inc.
Industry Competition: The company faces significant competition from other contract research organizations (CROs) and biotechnology firms. As of September 28, 2024, its revenue decreased by 1.6% year-over-year, reflecting pressures from competitors in the market.
Regulatory Changes: Regulatory scrutiny is increasing, particularly concerning the non-human primate supply chain. Legal costs related to this issue contributed to a 20.9% decline in operating income for the Discovery Services and Safety Assessment segments during the nine months ended September 28, 2024 compared to the same period in 2023.
Market Conditions: Economic fluctuations have affected the company's revenue streams, with total revenue for the nine months ended September 28, 2024, at $3,047.4 million, down from $3,115.9 million in the prior year, a decline of 2.2%.
Operational Risks:
Operational risks include disruptions in service delivery and project execution. Restructuring activities have incurred charges of $30.6 million and $65.6 million during the three and nine months ended September 28, 2024, respectively, impacting operational efficiency.
Financial Risks:
Financial risks encompass fluctuating interest rates and debt levels. Interest expense for the nine months ended September 28, 2024, was $98.1 million, a decrease of 5.0% compared to $103.2 million in the same period in 2023, due to lower debt balances.
Strategic Risks:
Strategic risks include challenges related to mergers and acquisitions. The recent acquisition of Noveprim has resulted in increased amortization costs, contributing to a decrease in operating income as a percentage of revenue for the nine months ended September 28, 2024, which was 13.0%, down from 15.5% in the same period in 2023.
Mitigation Strategies:
The company has initiated restructuring efforts aimed at achieving annualized cost savings of approximately $200 million, with about $100 million expected to impact fiscal year 2024. These strategies are designed to enhance operational efficiency and adapt to market changes.
| Risk Factor | Details | Financial Impact |
|---|---|---|
| Industry Competition | Increased competition from CROs and biotech firms | Revenue decreased by 1.6% year-over-year |
| Regulatory Changes | Heightened scrutiny in non-human primate supply chain | Legal costs contributed to a 20.9% decline in operating income |
| Market Conditions | Economic fluctuations affecting revenue streams | Total revenue down to $3,047.4 million, a 2.2% decline |
| Operational Risks | Disruptions in service delivery | Restructuring charges of $30.6 million and $65.6 million |
| Financial Risks | Interest rate fluctuations and debt levels | Interest expense decreased to $98.1 million |
| Strategic Risks | Challenges from mergers and acquisitions | Operating income as a percentage of revenue decreased to 13.0% |
| Mitigation Strategies | Restructuring for cost savings | Estimated annualized savings of $200 million |
Future Growth Prospects for Charles River Laboratories International, Inc. (CRL)
Future Growth Prospects for Charles River Laboratories International, Inc.
Analysis of Key Growth Drivers
Product Innovations: The company has been focusing on expanding its product line, particularly in the Biologics Testing and CDMO services. In the nine months ended September 28, 2024, manufacturing revenue increased by $44.9 million primarily due to higher demand for these services.
Market Expansions: The company's revenue from the RMS segment increased by 4.8%, amounting to $625.1 million in the nine months ended September 28, 2024. This growth is attributed to the recent acquisition of Noveprim, which contributed $30.0 million to the revenue.
Acquisitions: The acquisition of Noveprim has significantly bolstered the company’s research model product revenue, highlighting the strategic importance of acquisitions in its growth strategy.
Future Revenue Growth Projections and Earnings Estimates
The total revenue for the nine months ended September 28, 2024, was $3.047 billion, a decrease of 2.2% compared to $3.116 billion in the prior year. However, manufacturing revenue is expected to continue growing due to the rising demand in biologics.
Operating income for the nine months ended September 28, 2024, was $395.0 million, reflecting an operating income percentage of 13.0%. The company anticipates achieving approximately $200 million in cost savings on an annualized basis from restructuring efforts, with around $100 million impacting fiscal year 2024.
Strategic Initiatives or Partnerships That May Drive Future Growth
The company has initiated a restructuring plan expected to lead to significant cost savings, which will allow for reinvestment in high-growth areas. Additionally, the ongoing focus on expanding service offerings and enhancing operational efficiency positions the company well for future growth.
Competitive Advantages That Position the Company for Growth
The company benefits from a strong operational footprint globally, with long-lived assets of $1.640 billion as of September 28, 2024. Its diversified service lines, including Safety Assessment and Discovery Services, allow it to cater to a broad range of client needs, enhancing customer retention and attracting new business.
In addition, the company's strategic acquisitions, such as Noveprim, enhance its market position by expanding its product offerings and increasing revenue streams.
| Key Metrics | 2024 (Nine Months Ended September 28) | 2023 (Nine Months Ended September 30) | Change |
|---|---|---|---|
| Total Revenue | $3.047 billion | $3.116 billion | -2.2% |
| Manufacturing Revenue | $574.4 million | $529.5 million | +8.5% |
| Operating Income | $395.0 million | $484.3 million | -18.4% |
| Operating Income % of Revenue | 13.0% | 15.5% | -250 bps |
| Cash Flow from Operations | $575.2 million | $463.0 million | +24.2% |
Charles River Laboratories International, Inc. (CRL) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Updated on 16 Nov 2024
Resources:
- Charles River Laboratories International, Inc. (CRL) Financial Statements – Access the full quarterly financial statements for Q3 2024 to get an in-depth view of Charles River Laboratories International, Inc. (CRL)' financial performance, including balance sheets, income statements, and cash flow statements.
- SEC Filings – View Charles River Laboratories International, Inc. (CRL)' latest filings with the U.S. Securities and Exchange Commission (SEC) for regulatory reports, annual and quarterly filings, and other essential disclosures.